---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-058380"
form_type: "8-K"
ticker: "INMB"
cik: "0001711754"
company_name: "Inmune Bio, Inc."
filed_at: "2025-06-26T23:59:59+00:00"
generated_at: "2026-05-18T18:00:34.446849+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# INmune Bio to announce top line Phase 2 MINDFuL Alzheimer's data on June 30

## Summary
- Conference call scheduled for June 30, 2025 at 8:00 AM ET to present top line Phase 2 MINDFuL results.
- MINDFuL trial is a Phase 2 study in early Alzheimer's disease.
- Press release issued June 26, 2025 announcing the upcoming data call.
- Dial-in: +1-800-267-6316 (US) or +1-203-518-9783 (international), Conference ID: INMUNE.
- Replay available through July 30, 2025.

## SEC filing metadata
- accession: 0001213900-25-058380
- form_type: 8-K
- ticker: INMB
- cik: 0001711754
- company_name: Inmune Bio, Inc.
- filed_at: 2025-06-26T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711754/000121390025058380/0001213900-25-058380-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711754/000121390025058380/ea0247096-8k_inmune.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-058380
- JSON: https://secwatch.observer/filing/0001213900-25-058380.json
- Plain text: https://secwatch.observer/filing/0001213900-25-058380.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.